Catalyst
Slingshot members are tracking this event:
Alkermes ARISTADA, which treats patients with schizophrenia, seeking FDA approval for two-month dose in 2017
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| ALKS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Mar 20, 2017
Occurred Source:
http://phx.corporate-ir.net/phoenix.zhtml?c=92211&p=irol-newsArticle&ID=2255089
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Aristada, Schizophrenia
